Next Pharmaceuticals Announces a New Clinical Study Demonstrating Relora Significantly Relieves Short-Term Anxiety in Healthy Women

SALINAS, Calif.--(BUSINESS WIRE)--May 8, 2008 - Next Pharmaceuticals announced today the results of a six-week, double-blind, placebo-controlled clinical study on Relora conducted on healthy women between the ages of 20 and 50. Relora significantly reduced short-term anxiety compared to the placebo group. The study conducted by Miami Research Associates, a clinical research organization in Miami, Florida, was published in Nutrition Journal, an open access peer-reviewed, online journal. Nutrition Journal can be referenced through BioMed Central and PubMed.

"This is the first clinical study on Relora involving healthy women," said Charles Kosmont, Chairman and CEO of Next Pharmaceuticals. "Because the trial was geared towards this demographic, our customers can now promote Relora to a larger consumer base. There are many who suffer from short-term anxiety that do not want to be on medication. Relora may be the perfect alternative." The results of this study correlate with recent research that has established a connection between anxiety and stress as it relates to sleeplessness and weight gain.

The subjects reported that they have suffered from anxiety and they typically eat more in response to stressful situations. The intervention was 250 mg capsules of Relora or identical placebo three times daily for six weeks. Short-term anxiety was measured by the Spielberger STATE questionnaire. There were no safety concerns or significant adverse events observed in the study.

Relora is a proprietary blend of ingredients consisting of extracts of Magnolia officinalis bark and Phellodendron amurense bark. This patented blend of plant extracts is the result of screening more than fifty plant fractions from traditional plant medicines used around the world. Relora has excellent stress management properties without causing sedation.

Next Pharmaceuticals develops new, patented, natural ingredients for healthy living products in the dietary supplement, food and beverage industries. The goal of the Company is to expand self-care and preventative health maintenance. Next has successfully developed six plant extracts, both patented and proprietary, plus Chromulin(TM), a new form of the essential trace mineral chromium for potentiating insulin. These products have significantly expanded the choices for self-care products, while providing large consumer brands with powerful product differentiation. Through the application of pharmaceutical technologies to natural botanical materials, including citrus fruits, Next has developed Relora(R) for relaxation and stress-related appetite control, Seditol(R) for better quality of sleep, Nexrutine(R) for inflammation, Citri-Z(R) for heart health; Flavoxine(TM) for healthy cholesterol, and Citrofen(TM) for mobility and joint comfort.

For all media inquires, please contact Connie St John, 415-454-2243 or connie@stjohnpr.com.

Contact

for Next Pharmaceuticals
Connie St John, 415-454-2243
connie@stjohnpr.com

Posted: May 2008

View comments

Hide
(web5)